JP2021521128A5 - - Google Patents
Info
- Publication number
- JP2021521128A5 JP2021521128A5 JP2020555164A JP2020555164A JP2021521128A5 JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5 JP 2020555164 A JP2020555164 A JP 2020555164A JP 2020555164 A JP2020555164 A JP 2020555164A JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- heterocyclyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659068P | 2018-04-17 | 2018-04-17 | |
| US62/659,068 | 2018-04-17 | ||
| US201862746843P | 2018-10-17 | 2018-10-17 | |
| US62/746,843 | 2018-10-17 | ||
| PCT/US2019/027992 WO2019204523A1 (en) | 2018-04-17 | 2019-04-17 | Bicyclic carboxamides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521128A JP2021521128A (ja) | 2021-08-26 |
| JP2021521128A5 true JP2021521128A5 (enExample) | 2022-04-11 |
| JP7361713B2 JP7361713B2 (ja) | 2023-10-16 |
Family
ID=66625250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555164A Active JP7361713B2 (ja) | 2018-04-17 | 2019-04-17 | 二環式カルボキサミドおよびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10968201B2 (enExample) |
| EP (1) | EP3781550B1 (enExample) |
| JP (1) | JP7361713B2 (enExample) |
| KR (1) | KR102815312B1 (enExample) |
| CN (1) | CN112313208B (enExample) |
| AU (2) | AU2019255717B2 (enExample) |
| BR (1) | BR112020021042A2 (enExample) |
| CA (1) | CA3096894A1 (enExample) |
| DK (1) | DK3781550T3 (enExample) |
| ES (1) | ES3010282T3 (enExample) |
| IL (1) | IL277963B2 (enExample) |
| MX (1) | MX2020010879A (enExample) |
| SG (1) | SG11202010153WA (enExample) |
| WO (1) | WO2019204523A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| WO2018195123A1 (en) | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US10968201B2 (en) * | 2018-04-17 | 2021-04-06 | Tempest Therapeutics, Inc. | Bicyclic carboxamides and methods of use thereof |
| WO2022257961A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| WO2022257960A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的双环化合物 |
| CN114085167A (zh) * | 2021-12-13 | 2022-02-25 | 华中药业股份有限公司 | 一种杂质ts-3a的制备方法 |
| WO2024102968A1 (en) * | 2022-11-10 | 2024-05-16 | Tempest Therapeutics, Inc. | Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) |
| WO2024120512A1 (zh) * | 2022-12-08 | 2024-06-13 | 武汉人福创新药物研发中心有限公司 | 一种ep2、ep4受体拮抗剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| JP2007023028A (ja) * | 2005-06-16 | 2007-02-01 | Ono Pharmaceut Co Ltd | 内耳疾患治療剤 |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| JP5408434B2 (ja) | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | アミド化合物 |
| EP2565191B1 (en) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010121382A1 (en) | 2009-04-21 | 2010-10-28 | Merck Frosst Canada Ltd. | Process for making indole cyclopropyl amide derivatives |
| KR101664517B1 (ko) | 2009-04-21 | 2016-10-11 | 애플 인크. | 다중 사용자-ｍｉｍｏ 통신 네트워크에서의 채널 품질 지수를 결정하는 방법 및 장치 |
| EP2482849B1 (en) | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| BR112013003600A2 (pt) * | 2010-08-17 | 2016-08-16 | Allergan Inc | agonistas ep2 ou ep4 para o tratamento de névoa da córnea |
| WO2013045413A1 (en) * | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2999469A1 (de) | 2013-05-23 | 2016-03-30 | Bayer Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen ( on-demand") kontrazeption |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
| CN108430992A (zh) | 2015-12-17 | 2018-08-21 | 阿斯特克斯医疗公司 | 作为h-pgds抑制剂的喹啉-3-甲酰胺 |
| AR107354A1 (es) * | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
| PT3482760T (pt) | 2016-07-07 | 2021-12-15 | Ono Pharmaceutical Co | Combinação compreendendo antagonista de ep4 e inibidor de ponto de verificação imunitário |
| WO2018195123A1 (en) * | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US11066405B2 (en) | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| US10968201B2 (en) | 2018-04-17 | 2021-04-06 | Tempest Therapeutics, Inc. | Bicyclic carboxamides and methods of use thereof |
| WO2022257961A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| CN119487006A (zh) * | 2022-02-24 | 2025-02-18 | 广东新契生物医药科技有限公司 | 作为pge2受体拮抗剂的酰胺化合物 |
-
2019
- 2019-04-17 US US16/387,294 patent/US10968201B2/en active Active
- 2019-04-17 DK DK19725441.0T patent/DK3781550T3/da active
- 2019-04-17 IL IL277963A patent/IL277963B2/en unknown
- 2019-04-17 CN CN201980040841.6A patent/CN112313208B/zh active Active
- 2019-04-17 CA CA3096894A patent/CA3096894A1/en active Pending
- 2019-04-17 SG SG11202010153WA patent/SG11202010153WA/en unknown
- 2019-04-17 AU AU2019255717A patent/AU2019255717B2/en active Active
- 2019-04-17 EP EP19725441.0A patent/EP3781550B1/en active Active
- 2019-04-17 MX MX2020010879A patent/MX2020010879A/es unknown
- 2019-04-17 JP JP2020555164A patent/JP7361713B2/ja active Active
- 2019-04-17 ES ES19725441T patent/ES3010282T3/es active Active
- 2019-04-17 BR BR112020021042-0A patent/BR112020021042A2/pt active IP Right Grant
- 2019-04-17 KR KR1020207032916A patent/KR102815312B1/ko active Active
- 2019-04-17 WO PCT/US2019/027992 patent/WO2019204523A1/en not_active Ceased
-
2020
- 2020-10-14 US US17/070,554 patent/US11472789B2/en active Active
-
2022
- 2022-06-23 US US17/847,811 patent/US11795156B2/en active Active
-
2023
- 2023-02-28 AU AU2023201228A patent/AU2023201228A1/en not_active Abandoned
- 2023-09-14 US US18/467,022 patent/US12215093B2/en active Active
-
2024
- 2024-12-19 US US18/988,376 patent/US20250353829A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521128A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| DK2958907T3 (en) | Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2022529642A5 (enExample) | ||
| JP2022507020A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| JP2019535744A5 (enExample) | ||
| JP2021508686A5 (enExample) | ||
| JP2021523221A5 (enExample) | ||
| RU2011107278A (ru) | Пиримидиновые соединения, композиции и способы применения | |
| JP2013056886A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| RU2014122335A (ru) | ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ | |
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| JP2018504437A5 (enExample) | ||
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| JP2015531764A5 (enExample) | ||
| JP2022071077A5 (enExample) | ||
| JP2020535124A5 (enExample) | ||
| JP2014521609A5 (enExample) | ||
| JP2020507625A5 (enExample) | ||
| JP2020507624A5 (enExample) |